Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride

EU orphan designation number: EU/3/16/1657   
Active ingredient: (R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride
Indication: Treatment of biliary tract cancer
Sponsor: QRC Consultants Ltd
Silvaco Technology Centre, Compass Point, St Ives, Cambridgeshire PE27 5JL, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page
Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
01/06/2016 Orphan designation EMA/OD/245/15 (2016)3412 of 30/05/2016
22/08/2016 Transfer of orphan designation EMA/OD/245/15/T/01 (2016)5454 of 18/08/2016